NXTC, US65343E2072

NextCure stock falls 2.55 percent as merger faces court risk

Published on 10/05/2026 at 20:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NextCure stock traded at USD 4.96 on October 5, 2026, with a USD 17.9 million market value. Q2 net loss was USD 14.892 million, and a court hearing is set for November 6.

NXTC, US65343E2072, Illustration mit AI erstellt.

NextCure stock (ISIN US65343E2072) was trading at USD 4.96 on Nasdaq at 2:08 p.m. ET on October 5, 2026, down 2.55 percent from USD 5.09. The proposed merger with Avere Therapeutics remains tied to a Delaware court process, while an amended registration statement was filed on September 30, according to DataTooza.

Merger filing meets court scrutiny

The amended S-4/A updates the proposed transaction under which Avere would become the operating company and NextCure would change its name and ticker after closing, DataTooza reported. The transaction structure gives the legal validation of NextCure's 2025 reverse split direct importance for the deal.

In a September 21 Form 8-K, the SEC filing said the Court of Chancery scheduled a hearing for 3:00 p.m. ET on November 6, 2026. Stockholders can file written positions by October 27, 2026, and the filing states that an unsuccessful petition could delay or prevent the proposed business combination.

Q2 loss narrows year over year

For Q2 2026, NextCure reported a net loss of USD 14.892 million, or USD 2.80 per diluted share, compared with a USD 26.808 million loss and USD 11.29 per share in Q2 2025, according to Stock Titan.

Cash, cash equivalents and marketable securities stood at USD 20.088 million on June 30, 2026, down from USD 41.818 million on December 31, 2025, while research and development expense fell to USD 7.425 million from USD 24.091 million a year earlier, Stock Titan reported.

Stock sits below yearly high

At USD 4.96 on October 5, 2026, NextCure stock was 68.5 percent below its 52-week high of USD 15.74 and stood above its 52-week low of USD 1.55. The market capitalization was USD 17.9 million and trading volume was 6,264 shares at the same intraday snapshot.

The price places the legal timetable ahead of the next financial checkpoint. For investors assessing NXTC, the November hearing, the October 27 submission deadline and the proposed corporate transition are the concrete dates that frame the stock's near-term risk profile.